Meer, J.W. van der

trova floxacin abscess floxacin trova fragili treatment 5 days ef ficacy model count effect concentration weight infection ficacy regimen signi abscess weights 3 days inoculation 99 mtc-hynic igg reduction study agent fragilis-e antibiotic combination serum trova floxacin concentrations activity ficant chemother fi ndings antimicrobial animal signi ficantly pharmacokinetic bacteroides fragilis antimicrob netherland subcutaneou agents chemother 300 mg /kg dosing number q 24h regimens dosing regimens q 24h fragilis atcc 23745 serum protein binding difference signi ficant parameter strain binding pharmacodynamic culture fragilis-vref /absces bacteroide balb /c mice vivo ef ficacy result signi ficant difference abscess /skin ratios correlation coli combination regression analysis subcutaneous abscesses coli abscesses decrease stearne abscess weight escherichia coli ratio variation vivo efficacy nding antimicrobial agents pharmacokinetic studies